Key result
Regadenoson causes fewer side effects like AV block and bronchospasm than adenosine during stress imaging.
Why the study?
Regadenoson was approved in 2008 as a selective A(2A) agonist for vasodilator stress MPI, offering fixed-dose bolus administration and fewer side effects than adenosine.
Does regadenoson provide an effective and safer alternative to adenosine for stress myocardial perfusion imaging?
Comparison
Regadenoson vs adenosine
Design
Review
Authors
Loading...
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We don't know if this risk of MI with regadenoson is different from the risk with adenosine or other stress agents or exercise. What do you do? If you are not going to do this stress test, are you going to go straight to angiography? Do you do other stress agents? We don't have that comparative data. What we know is that the risk is relatively low.”
“As soon as regadenoson was approved, a lot of physicians were saying, 'Now we have a medicine that can be given as a bolus injection. I wonder if you can give it as needed.' Put them on a treadmill and if they didn't reach the target heart rate, pull a syringe out of your pocket and inject them. People started doing that right away without any real data to show it was safe.”
“It is faster, easier to use, has less side effects and has less of a chance for complications, such as bradycardia or asthma attacks, but it costs more.”
Regadenoson is a selective A(2A) agonist that offers a safer and more convenient alternative to adenosine for vasodilator stress MPI, particularly in patients with mild-to-moderate reactive airway disease.
Does regadenoson provide an effective and safer alternative to adenosine for stress myocardial perfusion imaging?
Regadenoson is a selective A(2A) agonist that offers a safer and more convenient alternative to adenosine for vasodilator stress MPI, particularly in patients with mild-to-moderate reactive airway disease.
Jaroudi et al. (2009) conducted a review in Myocardial perfusion imaging. Regadenoson vs. Adenosine was evaluated. Regadenoson is a selective A(2A) agonist approved for stress myocardial perfusion imaging that offers fewer undesirable side effects, such as AV block and bronchospasm, compared to adenosine.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: